The short version. Eighteen providers, and the coverage is lopsided in a way worth understanding before you read any single comparison. Three companies appear on eight of our pages each. Six appear on exactly one. That is not editorial favouritism, it is a direct function of how much each company publishes: a provider that puts prices, formats and regulatory status on its own site can be compared on all three, and one that puts a consultation form where a price should be can only be noted. The single most useful thing any company on this list could do for its own coverage is publish more.
01 / 04How to read the depth column
The number beside each provider is how many RxGrab comparisons name them. It is a measure of our coverage, not of their size or quality, and it moves for one reason above all others: what they publish.
A company that publishes a price by format, states whether a medication is compounded, and names the pharmacy that makes it can be placed in a pricing comparison, a format comparison and a regulatory comparison. A company that publishes a consultation form appears once, as a row that says “not published”. Both are honest outcomes and only one of them is within the company’s control.
02 / 04The eighteen
| Provider | Our pages | Model | What we found |
|---|---|---|---|
| Hims | 8 | reseller | sells branded Wegovy and Zepbound; the word “compound” does not appear on its weight-loss page; publishes an enclomiphene explainer but not a price |
 Ro | 8 | reseller | branded line-up; membership from $39 first month then $74 to $149, with medication stated as not included |
 Henry Meds | 8 | compounder | oral semaglutide at $179/mo; ⭐ the strongest disclosure we found anywhere: warns explicitly against transferring trial data from approved drugs to compounded ones |
 Strut Health | 5 | compounder | dose-tiered enclomiphene at $79, $99 and $119; uses “pharmacy-compounded” but we found no FDA-approval statement |
 Hone Health | 4 | both | the only provider publishing testosterone by format: injection $28, cream $60, troche $60, enclomiphene $42, all with a $135 or $155 membership separate |
 Defy Medical | 4 | clinic | clinic model with labs billed separately; no per-format price published on the pages we could reach |
 Maximus | 3 | clinic | protocol-based; no monthly price published on the page we read |
| 3 | clinic | labs-first coaching model, explicitly not a prescription-first service | |
| 2 | compounder | sublingual and rapid-dissolve specialist across several lines; states plainly that compounded medications are not FDA-approved; does not publish a dose against its enclomiphene price or name its compounding pharmacy | |
 Trimi | 2 | compounder | ⭐ the only provider in this index that names the pharmacies making its medicine: BelieveRx and GreenwichRx, state-licensed 503A |
 Lemonaid Health | 2 | reseller | lowest published per-dose ED pricing in our comparison |
| 2 | consult only | consultation without medication; you fill the prescription yourself | |
 Shed | 1 | compounder | injections, sublingual drops and dissolvable lozenges; no price published |
| PlexusDx | 1 | compounder | widest format range we found, six compounds across tablet, troche, capsule, lozenge and sublingual; no price published |
 Ready Med | 1 | compounder | oral semaglutide headlined at $249/mo, with a $297 membership including medication described lower on the same page |
| Tactus Health | 1 | compounder | states that sermorelin and PT-141 are the only two peptides it considers legally compoundable; requires consultation and labs |
 Ivy Rx | 1 | compounder | publishes a sermorelin cost guide, which is more than most of this category does |
 BlueChew | 1 | compounder | chewable ED tablets; figures read from its own checkout rather than its marketing pages |
Counts measured from the live RxGrab pages on 23 September 2026 by name and domain match. Model labels describe what each company’s own pages say it sells, and are explained in who compounds and who resells.
03 / 04The thing almost nobody publishes
Read the right-hand column of that table for a minute and one absence dominates it. Of eighteen companies, one names the pharmacy that actually makes the medicine.
Every compounded prescription is prepared by a specific, state-licensed, inspectable facility with a name. Trimi publishes its two. Nobody else in this index does. ⭐ It is the most checkable fact in this entire category and it is almost universally withheld, which is strange, because it is also the cheapest possible thing to publish and the one most likely to reassure a cautious buyer.
The second absence is price. Nine of the eighteen publish no monthly figure we could reach without entering an intake. That is a legitimate business choice and it has a direct consequence: a company whose price is a conversation cannot appear in a price comparison, on this site or anywhere else.
04 / 04How a provider gets covered here
There is no application and no fee. We build comparisons around what buyers search for, then read every provider’s own live pages and record what they publish. A company enters the index by being findable and publishing something comparable.
What increases coverage, in order of how much difference it makes: publish a price and say what it includes; state whether a preparation is compounded or an approved product; name the compounding pharmacy; publish by format rather than as a single “from” figure. Any one of those moves a company from a row that says “not published” into a row that can be compared, and a comparable row is the one that gets cited.
⛔ What does not increase coverage: paying us. Position in these comparisons and the verdicts in them are not for sale, which is stated on every page and is the reason the comparisons are worth reading at all. Where a placement is paid for, it is labelled where it appears and its link carries a sponsored attribute.
- Compounded GLP-1: cost and legal standing. Prices and the 503A/503B position.
- Who compounds and who resells. The model classification used in this index.
- Rapid-dissolve and sublingual formats. Format pricing and the evidence gap.
- Testosterone delivery formats. Per-format cost and approval status.
- Enclomiphene cost and FDA status. Dose-tiered pricing and the 503A Bulks List position.
- Peptide telehealth. The July 2026 advisory committee vote and what it did not change.
Does a provider pay to appear in this index?
No. There is no fee and no application. Companies appear because they are named in a comparison, and they are named because they publish something that can be compared. Position and verdicts are not for sale on any page on this site.
Why do some providers appear on eight pages and others on one?
Almost entirely because of how much they publish. A company that publishes prices by format, states its compounding status and names its pharmacy can be placed in several different comparisons. A company that publishes a consultation form can only be noted once.
Which providers name their compounding pharmacy?
One, out of eighteen. Trimi names BelieveRx and GreenwichRx, both state-licensed 503A pharmacies. It is the most checkable fact in compounded medicine and almost nobody publishes it.
Is a provider low in this index worse than one high in it?
No, and the order should not be read that way. It is sorted by how many of our comparisons name each company, which measures our coverage rather than their quality. Several clinic-model providers publish little precisely because their pricing is set at consultation.